Moderna soars into the ranks of the world's top pharma players, now worth 3 Regenerons
As we got started this morning, there was quite a bit of interest in seeing if Moderna could break the $200 billion mark today on its market cap. The mRNA power player has seen its already steep stock price more than double in the past month — breaking the $100 billion ceiling a few weeks ago caused a few gasps — and the last few days has seen a sharp spike as the biotech laid out bullish prospects for its booster shot after nabbing a megabillion-dollar reward for its Covid-19 vaccine.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.